Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sinarest LP New
- Development stage
- Unknown
- Lead developer
- Centaur Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sinarest LP New is an approved oral combination small-molecule tablet manufactured by Centaur Pharmaceuticals. It contains three active ingredients: levocetirizine (2.5 mg), phenylephrine (10 mg), and paracetamol (500 mg). Levocetirizine is a non-sedating, third-generation antihistamine that selectively blocks histamine H1 receptors, relieving symptoms such as sneezing, runny nose, and watery eyes. Phenylephrine is an alpha-1 adrenergic receptor agonist that acts as a nasal decongestant by causing vasoconstriction of blood vessels in the nasal passages. Paracetamol (acetaminophen) is an analgesic and antipyretic that reduces pain and fever, likely by inhibiting prostaglandin synthesis in the central nervous system. Sinarest LP New is indicated for the symptomatic relief of the common cold, allergic rhinitis, and rhinosinusitis.
- Brand names
- Sinarest LP New
- Other names
- levocetirizine + paracetamol + phenylephrinelevocetirizine + phenylephrine + paracetamol
02
Targets
ADRA1A (α1A)ADRA1B (α1B)ADRA1D (α1D)HRH1 (Histamine H1 Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Sinarest LP New.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sinarest LP New.